1.28
price up icon5.79%   0.07
after-market 시간 외 거래: 1.30 0.02 +1.56%
loading
전일 마감가:
$1.21
열려 있는:
$1.21
하루 거래량:
338.07K
Relative Volume:
0.36
시가총액:
$11.58M
수익:
-
순이익/손실:
$-16.23M
주가수익비율:
-0.086
EPS:
-14.8777
순현금흐름:
$-15.31M
1주 성능:
-2.29%
1개월 성능:
-36.32%
6개월 성능:
-96.95%
1년 성능:
-90.15%
1일 변동 폭
Value
$1.21
$1.30
1주일 범위
Value
$1.15
$1.355
52주 변동 폭
Value
$1.15
$55.00

Genprex Inc Stock (GNPX) Company Profile

Name
명칭
Genprex Inc
Name
전화
512-537-7997
Name
주소
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Name
직원
13
Name
트위터
@genprex
Name
다음 수익 날짜
2026-03-30
Name
최신 SEC 제출 서류
Name
GNPX's Discussions on Twitter

Compare GNPX vs VRTX, REGN, ARGX, ALNY, ONC

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
GNPX icon
GNPX
Genprex Inc
1.28 10.94M 0 -16.23M -15.31M -14.88
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
441.70 113.01B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
753.93 79.87B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
840.87 51.51B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
333.39 45.29B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
319.94 34.41B 5.36B 287.73M 924.18M 2.5229

Genprex Inc Stock (GNPX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2021-01-26 개시 National Securities Buy
2019-04-29 개시 Noble Capital Markets Outperform

Genprex Inc 주식(GNPX)의 최신 뉴스

pulisher
Apr 15, 2026

Genprex director Longnecker sells shares worth $22 - Investing.com

Apr 15, 2026
pulisher
Apr 11, 2026

Surprises Report: What are the analyst revisions for Guess IncIs Genprex Inc stock a good investment in YEARWeekly Stock Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Apr 11, 2026
pulisher
Apr 10, 2026

GNPX Should I Buy - Intellectia AI

Apr 10, 2026
pulisher
Apr 08, 2026

US Stocks Recap: What is the PEG ratio of AXSM2026 WrapUp & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn

Apr 08, 2026
pulisher
Apr 02, 2026

Genprex Shares Hit Annual Low Despite Stronger-Than-Expected Earnings - AD HOC NEWS

Apr 02, 2026
pulisher
Apr 01, 2026

GNPX SEC FilingsGenprex Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 01, 2026
pulisher
Mar 30, 2026

Genprex (NASDAQ: GNPX) advances REQORSA trials, eyes diabetes gene therapy - Stock Titan

Mar 30, 2026
pulisher
Mar 30, 2026

Genprex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 30, 2026
pulisher
Mar 30, 2026

Published on: 2026-03-30 13:10:35 - baoquankhu1.vn

Mar 30, 2026
pulisher
Mar 29, 2026

Genprex, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 29, 2026
pulisher
Mar 27, 2026

Top Ranking Stock Picker From Congress Is Back Buying Small Cap Stocks Again: Here Are The Tickers - Benzinga

Mar 27, 2026
pulisher
Mar 26, 2026

IPO Launch: Whats the beta of Genprex Inc stock2026 Drop Watch & AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Mar 26, 2026
pulisher
Mar 25, 2026

Dip Buying: Will Genprex Inc benefit from green energy policiesQuarterly Profit Review & Free Long-Term Investment Growth Plans - baoquankhu1.vn

Mar 25, 2026
pulisher
Mar 24, 2026

GNPX Stock Chart | GENPREX INC (NASDAQ:GNPX) - ChartMill

Mar 24, 2026
pulisher
Mar 22, 2026

Performance Recap: What are the analyst revisions for Guess IncIs Genprex Inc stock a good investment in YEAR2026 Selloffs & Weekly Chart Analysis and Guides - baoquankhu1.vn

Mar 22, 2026
pulisher
Mar 20, 2026

Genprex, Inc.: Fundamental Analysis and Financial Ratings | 2DE | US3724463027 - marketscreener.com

Mar 20, 2026
pulisher
Mar 20, 2026

GNPX Earnings History & Surprises | EPS & Revenue Results | GENPREX INC (NASDAQ:GNPX) - ChartMill

Mar 20, 2026
pulisher
Mar 19, 2026

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting - BioSpace

Mar 19, 2026
pulisher
Mar 19, 2026

Genprex collaborators to present lung cancer data at AACR meeting By Investing.com - Investing.com Australia

Mar 19, 2026
pulisher
Mar 18, 2026

Genprex presents positive preclinical REQORSA data at AACR showing biomarkers and combo efficacy - TradingView

Mar 18, 2026
pulisher
Mar 18, 2026

Genprex Highlights New Reqorsa Preclinical Data at AACR - TipRanks

Mar 18, 2026
pulisher
Mar 18, 2026

GNPX: Genprex Researchers to Present at AACR 2026 with Promising Lung Cancer Data - GuruFocus

Mar 18, 2026
pulisher
Mar 18, 2026

Genprex collaborators to present lung cancer data at AACR meeting - Investing.com

Mar 18, 2026
pulisher
Mar 18, 2026

Genprex (NASDAQ: GNPX) posts positive preclinical data on REQORSA in NSCLC - Stock Titan

Mar 18, 2026
pulisher
Mar 13, 2026

New Highs: Will Genprex Inc benefit from green energy policiesTrade Risk Assessment & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn

Mar 13, 2026
pulisher
Mar 13, 2026

GNPX Technical Analysis | Trend, Signals & Chart Patterns | GENPREX INC (NASDAQ:GNPX) - ChartMill

Mar 13, 2026
pulisher
Mar 10, 2026

Genprex to Participate at BIO Europe Spring 2026 - GuruFocus

Mar 10, 2026
pulisher
Mar 10, 2026

GNPX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Mar 10, 2026
pulisher
Mar 06, 2026

Aug Closing: Will Genprex Inc outperform tech stocksMarket Activity Report & Weekly High Return Forecasts - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 06, 2026

Trend Recap: Will Genprex Inc outperform tech stocksWeekly Gains Report & Technical Confirmation Trade Alerts - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 01, 2026

Genprex receives patent approval in Australia for cancer therapy - Investing.com Nigeria

Mar 01, 2026
pulisher
Feb 28, 2026

Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying - Yahoo Finance

Feb 28, 2026
pulisher
Feb 28, 2026

GNPX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Feb 28, 2026
pulisher
Feb 27, 2026

Genprex (NASDAQ: GNPX) CMO has shares withheld to cover RSU taxes - Stock Titan

Feb 27, 2026
pulisher
Feb 27, 2026

Genprex (GNPX) CEO reports 9,330-share tax-withholding disposition - Stock Titan

Feb 27, 2026
pulisher
Feb 26, 2026

Congressional Trading Activity Insights - Intellectia AI

Feb 26, 2026
pulisher
Feb 26, 2026

Genprex bags major patent wins in Japan & Europe for REQORSA cancer therapy - Indian Pharma Post

Feb 26, 2026
pulisher
Feb 25, 2026

Genprex Advances Cancer Therapy Strategy with Key International Patents - AD HOC NEWS

Feb 25, 2026
pulisher
Feb 24, 2026

Genprex receives Japanese and European patents for cancer therapy By Investing.com - Investing.com India

Feb 24, 2026
pulisher
Feb 23, 2026

Genprex stock jumps on Japan, Europe patent approvals By Investing.com - Investing.com Nigeria

Feb 23, 2026
pulisher
Feb 23, 2026

Genprex stock jumps on Japan, Europe patent approvals - Investing.com

Feb 23, 2026
pulisher
Feb 23, 2026

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Feb 23, 2026
pulisher
Feb 23, 2026

GENPREX, INC.COMMON STOCKTim Moore Congressional Trade on Feb. 05, 2026 - Quiver Quantitative

Feb 23, 2026
pulisher
Feb 23, 2026

Genprex (GNPX) Gains Global Patent Approvals for Innovative Canc - GuruFocus

Feb 23, 2026
pulisher
Feb 23, 2026

Genprex Secures Key Global Patents for REQORSA Therapy - TipRanks

Feb 23, 2026
pulisher
Feb 23, 2026

Genprex receives Japanese and European patents for cancer therapy - Investing.com

Feb 23, 2026
pulisher
Feb 23, 2026

Genprex secures Japan, EU patents for REQORSA combos, bolstering Acclaim-3 IP and trial - TradingView

Feb 23, 2026
pulisher
Feb 23, 2026

New cancer patents support Genprex (NASDAQ: GNPX) Acclaim-3 trial - Stock Titan

Feb 23, 2026
pulisher
Feb 23, 2026

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer - Barchart.com

Feb 23, 2026
pulisher
Feb 22, 2026

Genprex Navigates a Pivotal Juncture Amid Clinical Progress and Financial Strain - AD HOC NEWS

Feb 22, 2026

Genprex Inc (GNPX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$54.26
price up icon 2.69%
$48.70
price down icon 0.25%
$99.47
price up icon 1.08%
$152.54
price up icon 3.76%
$146.74
price down icon 4.34%
ONC ONC
$319.94
price up icon 3.21%
자본화:     |  볼륨(24시간):